1. Al-​Momani E, Zla­to­pol­s­kiy BD, Sol­bach C, Reske SN, Machulla H-J. Syn­the­sis of 15-(4-[131I]iodo­phe­nyl)penta­deca­noic acid (p-​IPPA) via tin-​precursor using Chloramine-​T as an oxi­dant. J Radio­anal Nucl Chem 2010; 286:231–234.
  2. Bar­baro D, Ver­burg FA, Lus­ter M, Rei­ners C, Rubello D. ALARA in rhTSH-​stimulated post-​surgical thy­roid rem­nant abla­tion: what is the lowest rea­son­ably achie­va­ble acti­vity? Eur J Nucl Med Mol Ima­ging 2010; 37:1251-1254.
  3. Bischoff M, Bischoff G, Buck A, Von Baer A, Pauls S, Schef­fold F, Schult­heiss M, Geb­hard F, Reske SN. Inte­gra­ted FDG-​PET-CT: its role in the assess­ment of bone and soft tis­sue tumors. Arch Orthop Trauma Surg 2010; 130:819-827.
  4. Bom­bar­dieri E, Giam­ma­rile F, Akto­lun C, Baum RP, Bischof Del­a­loye A, Maf­fioli L, Mon­cayo R, Mor­tel­mans L, Pepe G, Reske SN, Cas­tel­lani MR, Chiti A. 131I/ 123I-​Metaiodobenzylguanidine (mIBG) sci­n­ti­gra­phy: pro­ce­dure gui­de­li­nes for tumour ima­ging. Eur J Nucl Med Mol Ima­ging 2010; 37:2436-2446.
  5. Diessl S, Ver­burg FA, Lus­ter M, Rei­ners C. E-​learning in medi­cine with nuclear medi­cine as an example. Nukle­ar­me­di­zin 2010; 49:125-127.
  6. Diessl S, Ver­burg FA, Hoern­lein A, Schu­mann M, Lus­ter M, Rei­ners C. Eva­lua­tion of an internet-​based e-​learning module to intro­duce nuclear medi­cine to medi­cal stu­dents: a fea­si­bi­lity study. Nucl Med Com­mun 2010; 31:1063-1067.
  7. Diet­lein M, Lus­ter M, Rei­ners C. Nuclear medi­cine the­rapy of dif­fe­ren­tia­ted thy­roid can­cer: Sta­tus quo. Onko­loge 2010; 16:678-689.
  8. Diet­lein M, Kobe C, Lus­ter M. Dif­fe­ren­tia­ted Thy­roid Can­cer: New Con­cept of Radio­i­odine Abla­tion. Der Nukle­ar­me­di­zi­ner 2010; 33:203-213.
  9. Due­ren C, Diet­lein M, Lus­ter M, Plenzig F, Steinke R, Grimm J, Groth P, Eich­horn W, Rei­ners C. The use of thy­ro­gen in the treat­ment of dif­fe­ren­tia­ted thy­roid car­ci­noma: an intrain­di­vi­dual com­pa­ri­son of cli­ni­cal effects and impli­ca­ti­ons of daily life. Exp Clin Endocri­nol Dia­be­tes 2010; 118:513-519.
  10. Freu­den­mann RW, Kölle M, Huwe A, Lus­ter M, Reske SN, Huber M, Lep­ping P, Wolf RC, Schonfeldt-​Lecuona C. Delu­sio­nal infe­sta­tion: neu­ral cor­re­la­tes and anti­psy­cho­tic the­rapy inves­ti­ga­ted by mul­ti­modal neu­ro­ima­ging. Prog Neu­ro­psy­cho­phar­ma­col Biol Psych­ia­try 2010; 34:1215-1222.
  11. Grei­ner J, Küfer R, Reske SN, Mar­tin V, Döh­ner H, Ring­hof­fer M. Metro­no­mic treat­ment with low-​dose tro­fos­fa­mide leads to a long-​term remis­sion in a pati­ent with docetaxel-​refractory advan­ced meta­sta­tic pro­state can­cer. Case Report Med. 2010; 395720:1-4.
  12. Hil­len­brand A, Varhaug JE, Brauck­hoff M, Pan­dev R, Haufe S, Dot­zen­rath C, Koberle R, Hoff­mann R, Klein G, Kad­mon M, Negele T, Hagieva T, Henne-​Bruns D, Lus­ter M, Weber T. Fami­lial non­me­dul­lary thy­roid carcinoma-​clinical rele­vance and pro­gno­sis. A European mul­ti­cen­ter study. ESES Vienna pre­sen­ta­tion. Lan­gen­becks Arch Surg 2010; 395:851-858.
  13. Hin­dorf C, Glat­ting G, Chiesa C, Lindén O, Flux G. EANM Dosi­me­try Com­mit­tee gui­de­li­nes for bone mar­row and whole-​body dosi­me­try. Eur. J. Nucl. Med. Mol. Ima­ging 2010; 37:1238-1250.
  14. Klet­ting P, Kull T, Bun­jes D, Mah­ren B, Lus­ter M, Reske SN, Glat­ting G. Radio­im­mu­n­o­the­rapy with anti-​CD66 anti­body: Impro­ving the bio­dis­tri­bu­tion using a phy­sio­lo­gi­cally based phar­ma­co­ki­ne­tic model. J. Nucl. Med. 2010; 51:484-491.mit freund­li­cher Unter­stüt­zung der Deut­schen José Car­re­ras Leukämie-​Stiftung e. V.
  15. Klet­ting P, Meyer C, Reske SN, Glat­ting G. Poten­tial of opti­mal preloading in anti-​CD20 anti­body radio­im­mu­n­o­the­rapy: An inves­ti­ga­tion based on phar­ma­co­ki­ne­tic mode­ling. Can­cer Bio­ther. Radio­ph­arm. 2010; 25:279-287.
  16. Kot­zerke J, Oehme L, Lind­ner O, Hell­wig D. Posi­tron emis­sion tomo­gra­phy 2008 in Ger­many - results of the query and cur­rent sta­tus. Nukle­ar­me­di­zin 2010; 49:58-64.
  17. Lass­mann M, Rei­ners C, Lus­ter M. Dosi­me­try and thy­roid can­cer: the indi­vi­dual dosage of radio­i­odine. Endocr Relat Can­cer 2010; 17:R161-172.
  18. Lus­ter M, Kar­ges W, Zeich K, Pauls S, Ver­burg FA, Dralle H, Glat­ting G, Buck AK, Sol­bach C, Neu­maier B, Reske SN, Mot­taghy FM. Cli­ni­cal value of 18F-​fluorodihydroxyphenylalanine posi­tron emis­sion tomo­gra­phy/com­pu­ted tomo­gra­phy (18F-​DOPA PET/CT) for detec­ting pheo­chro­mo­cy­toma. Eur J Nucl Med Mol Ima­ging 2010; 37:484-493.
  19. Lus­ter M, Kar­ges W, Zeich K, Pauls S, Ver­burg FA, Dralle H, Glat­ting G, Buck AK, Sol­bach C, Neu­maier B, Reske SN, Mot­taghy FM. Cli­ni­cal value of 18-​fluorine-fluorodihydroxyphenylalanine posi­tron emis­sion tomo­gra­phy/com­pu­ted tomo­gra­phy in the follow-​up of medul­lary thy­roid car­ci­noma. Thy­roid 2010; 20:527-533.
  20. Lus­ter M, Ver­burg FA, Scheid­hauer K. Dia­gno­stic ima­ging work up in multi-​nodular goi­ter. Minerva Endocri­nol 2010; 35:153-159.
  21. Lus­ter M, Diet­lein M. Wann Medi­ka­mente, wann Radio­jod, wann Op.? Der All­ge­mein­arzt 2010; 13:1-8.
  22. Lus­ter M. Die indi­vi­dua­li­sierte The­ra­pie des Schild­drü­sen­kar­zi­noms. Der Nukle­ar­me­di­zi­ner 2010; 33:201–202.
  23. Maier-​Funk C, Weber T, Lang G, Hugl S, Reske SN, Lus­ter M. Intra­tho­ra­cic meta­sta­tic spread of para­thy­roid car­ci­noma. Nukle­ar­me­di­zin 2010; 49:N62.
  24. Neu­maier B, Dei­sen­ho­fer S, Som­mer C, Sol­bach C, Reske SN, Mot­taghy F. Syn­the­sis and eva­lua­tion of 18F-​fluoroethylated ben­zo­thia­zole deri­va­ti­ves for in vivo ima­ging of amy­loid plaques in Alz­hei­mer's disease. Appl. Radiat. Isot. 2010; 68:1066-1072.
  25. Sal­va­tori M, Lus­ter M. Radio­i­odine the­rapy dosi­me­try in benign thy­roid disease and dif­fe­ren­tia­ted thy­roid car­ci­noma. Eur J Nucl Med Mol Ima­ging 2010; 37:821-828.
  26. Schreyögg J, Wel­ler J, Star­gardt T, Herr­mann K, Blue­mel C, Dechow T, Glat­ting G, Krause BJ, Mot­taghy F, Reske SN, Buck AK. Cost-​Effectiveness of Hybrid PET/CT for Sta­ging of Non-​Small Cell Lung Can­cer. J Nucl Med 2010; 51:1668-1675.
  27. Stok­kel MP, Hand­kie­wicz Junak D, Lass­mann M, Diet­lein M, Lus­ter M. EANM pro­ce­dure gui­de­li­nes for the­rapy of benign thy­roid disease. Eur J Nucl Med Mol Ima­ging 2010; 37:2218-2228.
  28. Ver­burg FA, Häns­cheid H, Biko J, Hate­gan MC, Lass­mann M, Kreissl MC, Rei­ners C, Lus­ter M. Dosimetry-​guided high-​activity 131I the­rapy in pati­ents with advan­ced dif­fe­ren­tia­ted thy­roid car­ci­noma: initial expe­ri­ence. Eur J Nucl Med Mol Imag. 2010; 37:896-903.
  29. Ver­burg FA, Lus­ter M. Low-​risk dif­fe­ren­tia­ted thy­roid car­ci­noma pati­ents still deserve I-131 rem­nant abla­tion after total thy­ro­idec­tomy. Minerva Chir 2010; 65:95-100.
  30. Ver­burg FA, Mader U, Kruit­wa­gen CL, Lus­ter M, Rei­ners C. A com­pa­ri­son of pro­gno­stic clas­si­fi­ca­tion sys­tems for dif­fe­ren­tia­ted thy­roid car­ci­noma. Clin Endocri­nol (Oxf) 2010; 72:830-838.
  31. Ver­burg FA, Stok­kel MPM, Düren C, Ver­kooi­jen RBT, Mäder U, van Isselt JW, Mar­lowe RJ, Smit JW, Rei­ners C, Lus­ter M. No sur­vi­val dif­fe­rence after suc­cess­ful 131I abla­tion bet­ween pati­ents with initi­ally low-​risk and high-​risk dif­fe­ren­tia­ted thy­roid can­cer. Eur J Nucl Med Mol Imag 2010; 37:276-283.
  32. Weber T, Cam­me­rer G, Schick C, Sol­bach C, Hil­len­brand A, Barth TF, Henne-​Bruns D, Bla­gieva R, Böhm BO, Reske SN, Lus­ter M. C-11 methio­nine posi­tron emis­sion tomo­gra­phy/com­pu­ted tomo­gra­phy loca­li­zes para­thy­roid ade­no­mas in pri­mary hyper­pa­ra­thy­ro­idism. Horm Metab Res. 2010; 42:209-214.
  33. Weber YG, Roeb­ling R, Kas­subek J, Hoff­mann S, Rosen­bohm A, Wolf M, Stein­bach P, Jurkat-​Rott K, Wal­ter H, Reske SN, Lehmann-​Horn F, Mot­taghy FM, Ler­che H. Com­pa­ra­tive ana­ly­sis of brain struc­ture, meta­bo­lism, and cogni­tion in myo­to­nic dys­tro­phy 1 and 2. Neu­ro­logy 2010; 74:1108-1117.